This narrative review explores the emerging role of locoregional therapy (LRT) in metastatic prostate cancer, highlighting evidence from randomized trials and observational studies. LRT, including prostate radiotherapy, radical prostatectomy, and ablation, may benefit select patients, particularly those with low-volume or oligometastatic disease. Advanced imaging integration such as prostate-specific membrane antigen positron emission tomography and evolving risk stratification systems supports more tailored approaches. While early outcomes are promising, prospective studies are needed to define LRT's optimal use in modern metastatic prostate cancer management. The treatment paradigm for metastatic prostate cancer continues to evolve with the integration of novel systemic therapy agents.
The Urologic clinics of North America. 2026 Mar 13 [Epub]
Ismail Ajjawi, Preston C Sprenkle, Joseph F Renzulli, Michael S Leapman
Department of Urology, Yale School of Medicine, New Haven, CT, USA., Department of Urology, Yale School of Medicine, New Haven, CT, USA. Electronic address: .